Cyclacel Pharmaceuticals Files 8-K
Ticker: BGMSP · Form: 8-K · Filed: Aug 13, 2025 · CIK: 1130166
Sentiment: neutral
Topics: financial-reporting, exhibits
Related Tickers: CYCC
TL;DR
Cyclacel Pharma filed an 8-K on Aug 13, 2025, with updated financials.
AI Summary
Cyclacel Pharmaceuticals, Inc. filed an 8-K on August 13, 2025, reporting financial statements and exhibits as of August 12, 2025. The company, formerly known as Xcyte Therapies Inc., is incorporated in Delaware and has its principal executive offices in Kuala Lumpur, Malaysia.
Why It Matters
This filing provides updated financial information and exhibits for Cyclacel Pharmaceuticals, Inc., which is crucial for investors to assess the company's current financial health and operational status.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- XCYTE THERAPIES INC (company) — Former company name
- August 12, 2025 (date) — Date of earliest event reported
- August 13, 2025 (date) — Date of report
FAQ
What is the primary purpose of this Form 8-K filing?
The primary purpose of this Form 8-K filing is to report financial statements and exhibits as of August 12, 2025.
When was the report filed with the SEC?
The report was filed with the SEC on August 13, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Cyclacel Pharmaceuticals, Inc.
What was the company's former name?
The company's former name was XCYTE THERAPIES INC.
Where are Cyclacel Pharmaceuticals, Inc.'s principal executive offices located?
Cyclacel Pharmaceuticals, Inc.'s principal executive offices are located at Level 10, Tower 11, Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia 592000.
Filing Stats: 463 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-08-13 06:17:57
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 495KB
- form8-k_001.jpg (GRAPHIC) — 14KB
- 0001641172-25-023296.txt ( ) — 828KB
- cycc-20250812.xsd (EX-101.SCH) — 4KB
- cycc-20250812_def.xml (EX-101.DEF) — 26KB
- cycc-20250812_lab.xml (EX-101.LAB) — 36KB
- cycc-20250812_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: August 12, 2025 Cyclacel Pharmaceuticals, Inc. By: /s/ Datuk Dr. Doris Wong Sing Ee Name: Datuk Dr. Doris Wong Sing Ee Title: Chief Executive Officer and Executive Director 3